Last updated: May 12, 2024
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Digestive System Neoplasms
Vomiting
Gastric Ulcers
Treatment
NEPA
Clinical Study ID
NCT06417567
NEPA
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Male or female, aged 18-65 years old; 2. The subjects were diagnosed withliver, gallbladder, and pancreatic diseases through histology or cytology andunderwent elective surgical treatment, including but not limited topancreaticoduodenectomy, liver resection, bile duct stone removal, etc., andreceived treatment with Netopitam Palonosetron capsules; 3. The subject is notin lactation period; 4. When screening female patients with potentialpregnancy, it is necessary to confirm that the pregnancy test must be negative;
- The subjects voluntarily and strictly comply with the research protocolrequirements and sign a written informed consent form.
Exclusion
Exclusion Criteria:
- Serious liver and kidney dysfunction, cardiopulmonary dysfunction, or otherserious diseases have not received standardized treatment; 2) Having a seriousmental illness in the past; 3) Take antiemetics or antidepressants within 48hours before surgery; 4) Patients receiving systemic glucocorticoid treatmentwithin 4 weeks prior to surgery; 5) Take NK1 receptor antagonists or anyinvestigational drugs within 4 weeks prior to the start of the experiment; 6)Use CYP3A4 inducer within 4 weeks prior to surgery, and CYP3A4 substrate orpotent, moderate CYP3A4 inhibitor within 1 week; 7) Pregnant or lactatingwomen, patients with fertility who are unwilling or unable to take effectivecontraceptive measures; 8) Drug and/or alcohol abuse; 9) Hypocalcemia or anyother condition that may cause vomiting; 10) The subject has an allergicreaction to Netopitam Palonosetron capsules or any of their excipients; 11)Participate in another clinical study within 30 days prior to baseline visit,using any exploratory drugs or devices; Allow participation in observationalresearch; 12) Researchers assess other situations that may affect the progressof clinical research and the determination of research results.
Study Design
Total Participants: 50
Treatment Group(s): 1
Primary Treatment: NEPA
Phase:
Study Start date:
May 15, 2024
Estimated Completion Date:
December 31, 2026
Connect with a study center
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin 300060
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.